Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.
Eroglu Z, Kim DW, Wang X, Camacho LH, Chmielowski B, Seja E, Villanueva A, Ruchalski K, Glaspy JA, Kim KB, Hwu WJ, Ribas A.
Eroglu Z, et al. Among authors: glaspy ja.
Eur J Cancer. 2015 Nov;51(17):2689-97. doi: 10.1016/j.ejca.2015.08.012. Epub 2015 Sep 10.
Eur J Cancer. 2015.
PMID: 26364516
Free PMC article.